Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 3, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:
2024年6月3日，馬薩諸塞州貝德福德——(美國商業資訊)——生物技術公司Stoke Therapeutics，Inc。（Nasdaq：STOK）致力於通過上調基於RNA的藥物的蛋白質表達來解決嚴重疾病的潛在原因，今天宣佈公司管理層將在以下即將舉行的投資者會議上進行演講：
Goldman Sachs 45th Annual Global Healthcare Conference
Date: Monday, June 10, 2024
Time: 4:00 p.m. ET
高盛第45屆全球保健大會
日期：2024年6月10日星期一
時間：東部時間下午4:00
TD Cowen Genetic Medicines & RNA Summit
Date: Thursday, June 20, 2024
Time: 10:00 a.m. ET
TD Cowen遺傳藥物和RNA峯會
日期：2024年6月20日星期四
時間：東部時間上午10:00
Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/.
每個事件的現場網絡廣播和網絡廣播的存檔重播將在Stoke網站的投資者和新聞部分上提供，網址爲https://investor.stoketherapeutics.com/。.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke's first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.
關於Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK) 是一家專注於通過上調基於RNA的藥物的蛋白質表達來解決嚴重疾病的生物技術公司。 使用Stoke專有的TANGO(有針對性的核基因輸出增強)方法，Stoke正在開發選擇性恢復蛋白質水平的反義寡核苷酸(ASOs)。Stoke的第一個化合物STK-001正在進行臨床試驗，用於治療Dravet綜合症，一種嚴重和漸進的遺傳性癲癇。 Dravet綜合症是許多疾病之一，這些疾病是由於半數失衡引起的，其中失去正常蛋白質水平的約50％會導致疾病。 Stoke正在追求開發STK-002，用於治療常染色體顯性視神經萎縮(ADOA)，這是最常見的遺傳性視神經病變。 Stoke的初始重點是半數失衡症和中樞神經系統和眼睛疾病，儘管已經在其他器官、組織和系統中證明了其專有方法的廣泛潛力，支持其廣闊的潛力。 Stoke的總部位於馬薩諸塞州貝德福德，另設辦事處於馬薩諸塞州劍橋市。 有關更多信息，請訪問https://www.stoketherapeutics.com/。.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603791457/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240603791457/en/
Stoke Investor Contact:
Eric Rojas
Vice President, Investor Relations
IR@stoketherapeutics.com
617-312-2754
Stoke投資者聯繫人：
Eric Rojas
投資者關係副總裁
IR@stoketherapeutics.com
617-312-2754
Source: Stoke Therapeutics, Inc.
資料來源：Stoke Therapeutics，Inc。
譯文內容由第三人軟體翻譯。